LAUSR

INTRODUCTION To report 2-year outcomes of intravitreal injection of high-dose conbercept (1 mg 2+PRN scheme) for subjects with myopic choroidal neovascularization (mCNV) and idiopathic choroidal neovascularization (iCNV) by optical coherence tomography angi-ography (OCTA) follow-up. METHODS A total of 38 subjects (38 eyes) were enrolled in this retrospective study, which were divided into group A (mCNV, 20 subjects, 20 eyes) and group B (iCNV, 18 subjects,18 eyes). All subjects received 1.0 mg of conbercept intravitre-ally at diagnosis and again 35 days later. Additional conbercept injection was administered upon findings of decreased best-corrected visual acuity (BCVA); metamorphosis aggrava-tion, macular hemorrhage, or edema; increased central retinal thickness (CRT); or leakage observed by fluorescein angiography (FA). The BCVA, CRT, and CNV area of the two groups were evaluated at baseline and at 1, 2, 4, 6, 12, and 24 months after surgery. RESULTS The BCVA of group A improved from 0.31 ±0.16 logMAR at baseline to 0.12 ± 0.03logMAR at the final follow-up (P < 0.001), while in group B the corresponding im-provement was from 0.33 ± 0.16logMAR at baseline to 0.12 ± 0.03logMAR at the final fol-low-up (P < 0.001). Visual acuity improved in 17 subjects in group A and 15 in group B, while it remained stable in 3 subjects each in groups A and B. CRT decreased from 311.83 ± 30.95 μm in group A and 351.17 ± 37.09 μm in group B pre-operation to 229.56 ± 5.75 μm and 227.67 ± 4.98 μm at 24 months follow-up, respectively (P < 0.001 in groups A and B). Metamorphopsia was improved in subjects in groups A and B. CNV had disappeared in the two groups at the last postoperative visit. The BCVA, CRT, and CNV area were no statisti-cal differences between the two groups at 6, 12, and 24 months follow-up (p > 0.05). Con-clusion: Intravitreal injection of conbercept (1 mg 2+PRN scheme) is effective for treating patients with mCNV or iCNV, which can improve and stabilize vision as well as dramatical-ly alleviate metamorphopsia.